New hope for advanced lung cancer: experimental drug SHR-1826 enters phase 2 trial
NCT ID NCT07489716
First seen Mar 24, 2026 · Last updated May 05, 2026 · Updated 5 times
Summary
This study tests a new drug called SHR-1826 in 90 adults with advanced or metastatic non-small cell lung cancer that has worsened after other treatments. Participants receive the drug by IV every three weeks. The goal is to see if the drug shrinks tumors and to check its safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, 250117, China
Contact
Conditions
Explore the condition pages connected to this study.